Last reviewed · How we verify
Lu AF82422
At a glance
| Generic name | Lu AF82422 |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Lu AF82422 in Participants With Multiple System Atrophy (PHASE2)
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (PHASE3)
- A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults (PHASE1)
- Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lu AF82422 CI brief — competitive landscape report
- Lu AF82422 updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI